Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-lung 8 trial
Goss, G. D., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., . . . Felip, E. (2021). … Read More
